MARKET

CYCCP

CYCCP

Cyclacel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.10
-0.10
-1.64%
Closed 16:00 04/01 EDT
OPEN
6.00
PREV CLOSE
6.10
HIGH
6.00
LOW
6.00
VOLUME
4
TURNOVER
--
52 WEEK HIGH
6.39
52 WEEK LOW
3.870
MARKET CAP
2.01M
P/E (TTM)
-12.1065
1D
5D
1M
3M
1Y
5Y

CYCCP News

More
  • Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 02/27 01:43
  • Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
  • GlobeNewswire · 02/26 21:05
  • Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?
  • Zacks · 02/20 13:50
  • Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results
  • GlobeNewswire · 02/19 12:00

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About CYCCP

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
More

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions.